Image 2_Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration.tif by Daniel E. Millian (20296458)

“…In parallel, spectral imaging further revealed post-treatment shifts in macrophage populations, with a significant decrease in inflammatory subsets (CD14+, CD14+/Mac387+, p<0.05) and an increase in anti-inflammatory subsets (CD16+, CD16+/CD163+, CD16+/CD68+, p<0.05). …”

Image 1_Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration.tif by Daniel E. Millian (20296458)

“…In parallel, spectral imaging further revealed post-treatment shifts in macrophage populations, with a significant decrease in inflammatory subsets (CD14+, CD14+/Mac387+, p<0.05) and an increase in anti-inflammatory subsets (CD16+, CD16+/CD163+, CD16+/CD68+, p<0.05). …”

Image 5_Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration.tif by Daniel E. Millian (20296458)

“…In parallel, spectral imaging further revealed post-treatment shifts in macrophage populations, with a significant decrease in inflammatory subsets (CD14+, CD14+/Mac387+, p<0.05) and an increase in anti-inflammatory subsets (CD16+, CD16+/CD163+, CD16+/CD68+, p<0.05). …”

Table 1_Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration.docx by Daniel E. Millian (20296458)

“…In parallel, spectral imaging further revealed post-treatment shifts in macrophage populations, with a significant decrease in inflammatory subsets (CD14+, CD14+/Mac387+, p<0.05) and an increase in anti-inflammatory subsets (CD16+, CD16+/CD163+, CD16+/CD68+, p<0.05). …”

Image 3_Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration.tif by Daniel E. Millian (20296458)

“…In parallel, spectral imaging further revealed post-treatment shifts in macrophage populations, with a significant decrease in inflammatory subsets (CD14+, CD14+/Mac387+, p<0.05) and an increase in anti-inflammatory subsets (CD16+, CD16+/CD163+, CD16+/CD68+, p<0.05). …”

Data Sheet 1_Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis.docx by Rita Spathis (187690)

“…</p>Results<p>Viral load was significantly increased by 77-fold in white blood cells after two rAAV9-microdystrophin doses compared to mice receiving a single dose. …”

Clinical and biochemical determinants of length of stay, readmission and recurrence in patients admitted with diabetic ketoacidosis by Fateen Ata (12217764)

“…<p>The increasing prevalence of diabetic ketoacidosis (DKA) related admissions poses a significant burden on the healthcare systems globally. …”

Ydj1 acetylation alters interactions with client proteins. by Siddhi Omkar (12413434)

“…Interactors are colored according to change in interaction as follows: green (significant increase), red (significant decrease), or purple (no significant change) 6KQ/6KR. …”

Signal denoising in modular spiking networks by Barna Zajzon (8083532)

“…These ordered projections arrange and preserve the relative organization of cells between distinct populations and have been the object of many empirical studies. From providing a structural scaffold for spatial information segregation to the organization of spatiotemporal feature maps, these ubiquitous anatomical features are known to have significant, albeit not entirely understood, functional consequences.…”

Figure 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma by Edgar Gonzalez-Kozlova (18366814)

“…<b>C,</b> Summary heatmap showing the log₂-fold change (log₂FC) between time points and treatments. The changes with a positive log₂FC over time in color blue are associated with a decrease over time and red with an increase over time. …”

Live/Dead cells 4 days incubation. by Takanori Kitagawa (20727226)

“…<div><p>Traditionally, the yeast cell wall (YCW) has limited applications because of its low solubility. To overcome this, a novel method was developed using a hydrothermal reaction to enhance its solubility and decrease its viscosity; this resulted in the production of a soluble form of YCW, known as the YCW treated with hydrothermal reaction (YCW-H), with broader chemical composition. …”

ESR Fig 4, Table 1 data. by Takanori Kitagawa (20727226)

“…<div><p>Traditionally, the yeast cell wall (YCW) has limited applications because of its low solubility. To overcome this, a novel method was developed using a hydrothermal reaction to enhance its solubility and decrease its viscosity; this resulted in the production of a soluble form of YCW, known as the YCW treated with hydrothermal reaction (YCW-H), with broader chemical composition. …”

Table 2_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.xlsx by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 2_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 7_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 6_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Table 1_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.xlsx by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 4_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 1_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 8_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”